Healthcare & Pharma
Precision FX for global life sciences operations.
Pharmaceutical companies, biotech firms, and medical device groups with international operations need FX infrastructure built for the complexity of global clinical trials, multi-continent supply chains, and multi-market revenue collection. Jackson Swiss Partners delivers institutional-grade execution — at every stage of your global value chain.
The FX Burden
Unmanaged FX is eroding margins at every stage of the value chain.
From API procurement in Asia to clinical trial operations across 50+ countries and revenue collection from international distributors, pharma groups face layered FX exposure that compounds silently — especially when managed through high-spread bank channels.
- Bank FX spreads on supply chain payments and intercompany transfers average 1.5–2.0% — applied across billions in procurement spend
- Unhedged clinical trial budgets absorb FX variance of 5–15% over a 12–24 month study — directly impacting R&D cost forecasts
- Revenue collected from international distributors suffers translation losses and settlement delays that erode receivables month after month
Estimated FX cost drag — pharma global operations
FX Exposure in Focus
Clinical trial FX coverage — 24-month programme
API ingredient sourcing — FX exposure by origin
Source: EY Global Pharma Report — industry estimates
Pharma treasury lifecycle — JSP FX touchpoints
The Solution
One platform for FX across the entire life sciences value chain
JSP wraps institutional FX infrastructure around every financial flow in your global pharma operations — from forward contracts that lock in clinical trial budgets to real-time supply chain payments in CNY/INR, and consolidated visibility across all entities and currencies.
- Forward contracts timed to clinical trial milestones protect R&D budgets from FX drift over 12–24 months
- Institutional rates on API and CDMO payments in 30+ currencies — including CNY, INR, BRL, and ZAR
- Consolidated real-time FX dashboard across all subsidiaries, trial accounts, and hedging positions
Core Capabilities
Built for global life sciences operations.
Clinical Trial FX
Forward contracts timed to trial milestones — hedge investigator fees, site costs, and CRO contracts across 50+ countries to protect R&D budgets.
Supply Chain Payments
Pay API manufacturers, CDMOs, and logistics partners in CNY, INR, and 30+ currencies at institutional rates — with same-day settlement and full documentation.
Revenue Collection
Receive distributor and hospital payments in local currencies via dedicated VIBANs — reducing conversion costs and reconciliation friction across all markets.
FX Hedging
Forward contracts and options for multi-currency COGS exposure, royalty streams, and long-dated supply agreements — structured around your planning cycle.
Intercompany FX
Institutional rates for transfer pricing settlements, IP royalty payments, and entity-to-entity funding — across all jurisdictions and legal structures.
Treasury Technology
Real-time dashboard across all entities, currencies, and hedging positions — consolidated exposure visibility built for global pharma treasury teams.
Measurable Impact
Why life sciences firms choose our approach.
international revenue
share for major pharma groups — creating substantial multi-currency exposure
countries
covered in a typical global Phase 3 clinical trial programme
currencies
supported for supply chain, clinical, and revenue collection operations
forward contracts
for locking clinical trial and supply chain FX rates against budget
FX spread comparison — institutional rates vs bank channels (common pharma currency pairs)
FAQ
Healthcare & pharma FX & treasury FAQ.
Get Started
Ready to protect margins across your global operations?
Speak to an advisor who understands the FX complexity of pharma supply chains, clinical trial budgets, and international revenue. Institutional pricing, forward hedging, consolidated treasury visibility.